Kornimate/medical-research-clean huggingface dataset:
rod sensitivity in age-related macular degeneration (amd) and retinitis pigmentosa (rp)

Conditions: Retinitis Pigmentosa; AMD

Summary: a new fundus-guided microperimeter (mp-3s) has been developed by nidek, inc. to track the fundus of the patient and present stimuli in specific anatomically-defined locations. furthermore, this tracking means that exactly the same locations can be tested on subsequent (follow-up) visits. the investigators will use a method called two-color perimetry to map rod and cone sensitivity on this device. with this technique, the sensitivity difference (blue-red) to chromatic test stimuli can be used to determine whether rods, cones or both photoreceptor systems mediate the threshold at a given location in the macula.

despite recent advances in understanding the pathogenesis of retinitis pigmentosa (rp) and age-related macular degeneration (amd), precise characterization of the disease phenotype remains elusive. in both diseases, much of the focus has necessarily been on the loss of cone function, since visual fields, acuity and contrast sensitivity are typically measured under photopic conditions. in rp, we need a greater understanding of patterns of rod loss since most disease-causing mutations affect primarily rods. in amd, recent findings have shown that scotopic sensitivity can be much more affected than conventional photopic measurements such as visual acuity. for patients, however, it is difficult to maintain stable fixation, especially when central vision is compromised. a new fundus-guided microperimeter, the mp-3s, has been developed by nidek, inc. to circumvent this problem. the investigators will evaluate the value of this device for following rod and cone loss in patients with either rp or amd.

Eligibility criteria:
inclusion criteria: * clear media * diagnosis of rp or non neovascular amd * normal volunteers exclusion criteria: * exudative amd * other eye diseases that could cause vision loss * physical ailments that would preclude comfortable testing * unable to provide informed consent

Keywords: microperimetry rod visual fields
comparison of two types of surgery in treating patients with rectal cancer

Conditions: Colorectal Cancer

Summary: rationale: surgery to remove the tumor may be an effective treatment for rectal cancer. it is not yet known whether one type of surgery is more effective than another for rectal cancer. purpose: randomized phase iii trial to compare the effectiveness of two types of surgery in treating patients who have rectal cancer.

objectives: * compare local and distant recurrences in patients with mid-rectal cancer treated with wide mesorectal surgical excision with straight colorectal anastomosis versus total mesorectal surgical excision with colonic j pouch coloanal anastomosis. * compare the functional, physiological, and anatomical outcomes in these patients treated with these two surgical procedures. * compare disease-free survival and overall survival in these patients treated with these two surgical procedures. outline: this is a randomized, multicenter study. patients are stratified according to treatment center. patients are randomized to 1 of 2 treatment arms. * arm i: patients undergo surgical resection with a wide mesorectal excision followed by a straight colorectal anastomosis. * arm ii: patients undergo surgical resection with a total mesorectal excision followed by a colonic j pouch coloanal anastomosis. patients then receive a temporary ileostomy which is closed 6 weeks later. patients are followed at 6 weeks, every 4-6 months for 2 years, every 6 months for 2 years, and then annually thereafter. projected accrual: a minimum of 800 patients (400 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: * clinical diagnosis of rectal cancer by colonoscopy or barium enema * distal margin of tumor arises within 9-15 cm from the anal verge as measured by rigid sigmoidoscopy * no synchronous multiple adenocarcinomas * candidate for low anterior surgical resection by laparoscopy or conventional open method * no evidence of gross metastatic disease * no evidence of peritoneal or pelvic metastases patient characteristics: age: * 18 and over performance status: * not specified life expectancy: * at least 6 months hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no other malignancy within the past 5 years prior concurrent therapy: biologic therapy: * not specified chemotherapy: * neoadjuvant or adjuvant chemoradiotherapy allowed endocrine therapy: * not specified radiotherapy: * see chemotherapy surgery: * see disease characteristics

Keywords: stage i rectal cancer stage ii rectal cancer stage iii rectal cancer
bands in peripheral blood after coronary artery bypass grafting with and without cardiopulmonary bypass

Conditions: Granulocyte Immature Forms; Inflammatory Response Syndrome, Systemic

Summary: coronary artery bypass graft (cabg) surgery is associated with reperfusion syndrome and activation of inflammatory reaction (sirs). these are more exaggerated when cardiopulmonary bypass (cpb) is used. the aim of the study is to compare signs of sirs (heart rate, tachypnea or hypocarbia, leukocytosis, hyperpyrexia or hypothermia) and the granulocytes subsets in peripheral blood from patients who underwent cabg surgery with or without use of cpb. the researchers expect significant differences in sirs criteria between both groups. if the differences will occur significant, the parameter may be used as candidate variable for a complications prediction model after cabg surgery.

patients fulfilling inclusion criteria will be asked to sign the consent to participate in the study, the day before operation after routine preoperative anesthesiological evaluation. if included into the study they will be assigned to one of the two study groups - off-pump cabg, or cabg with cpb. after arrival into the operating theatre 4.5 ml blood will be obtained into edta vials from a peripheral venous canula, placed previously for routine anesthesiologic management. additional blood samples will be obtained 3, 6, 12, 24 and 48 hours after the operation. each vial will be immediately labeled with an identification number and submitted into the laboratory, where smear with may-grunwald-giemsa staining will be prepared. the smear will be panoptical examined for 400 consecutive leucocytes and assigned to one of the following lines: neutrophils, eosinophils, basophils, monocytes and lymphocytes. neutrophils will be further divided into: segments, bands, metamyelocytes, myelocytes, promyelocytes, myeloblasts. the laboratory staff will be blinded for type of operation. differences in subsets of granulocytes between groups and timepoints wil be analysed as means by appropriate parametric or nonparametric statistical tests. the sirs criteria will be refered to: 1. intraoperative variables: number of distal anastomoses, time of aorta/artery clamping, time of intraoperative hypotension, suction pump use, serum lactates; 2. postoperative variables: serum crp, blood products transfusion, chest tube drainage.

Eligibility criteria:
inclusion criteria: * elective or urgent cabg with cpb or without (off-pump cabg) * signed informed consent exclusion criteria: * denied consent * signs of infection and/or inflammation (at least 2/4 sirs criteria) * emergency operation * organ failure/dysfunction

Keywords: cardiopulmonary bypass neutrophils coronary artery bypass graft surgery
developing a trauma-focused intervention for older adults living with hiv

Conditions: Trauma; Hiv; Aging

Summary: investigators are adapting the lift and reflect interventions for older adults living with hiv who have been exposed to childhood sexual abuse.


Eligibility criteria:
inclusion criteria: * living with hiv * 50 years old or older * \<100 % art adherence * depressive symptoms exclusion criteria: * not living with hiv * \<50 years * 100% art adherence
haptoglobin and preeclampsia

Conditions: Preeclampsia

Summary: the purpose of this study is to show that a certain protein called haptoglobin protects against preeclampsia which is a common pregnancy complication.


Eligibility criteria:
inclusion criteria: * all women exclusion criteria: * women with hypertension
a study of oncobax®-ak in patients with advanced solid tumors

Conditions: Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung

Summary: akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. analysis of the gut microbiota of nsclc or rcc patients shows that the presence of akkermansia is associated with the clinical efficacy of immunotherapy. in preclinical models, oral administration of the akkermansia p2261 strain reverses resistance to pd-1 blockade. in the clinical setting, it is therefore hypothesized that the oral administration of oncobax®-ak to cancer patients under immunotherapy, but whose gut microbiota is deficient in akkermansia will restore / improve the efficacy of immunotherapy in patients with nsclc or rcc.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years 2. histologically confirmed stage iv non-squamous nsclc or clear cell rcc 3. nsclc-specific criterion: best tumor response (by irecist) as stable disease 4. nsclc-specific criterion: pd-l1 expression \> 50% 5. ecog performance status = 0-1 6. negative stool pcr test for akkermansia 7. at least one measurable lesion per irecist 8. hemoglobin ≥ 100 g/l 9. albumin \> 35 g/l 10. signed informed consent exclusion criteria: 1. symptomatic brain metastases 2. ast or alt \> 5 x uln 3. calculated creatinine clearance \< 45 ml/min 4. auto-immune diseases requiring systemic therapy 5. immunosuppressive therapy (\> 10 mg prednisone/day equivalent) 6. radiotherapy (\> 30 gy) to the lung(s) within 6 months of signed informed consent 7. active infection 8. co-morbidities that may increase the risk of treatment-related adverse events 9. pregnancy 10. inability to comply with protocol-specific assessments
abiraterone acetate combined with dutasteride for metastatic castrate resistant prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic disease. this study will also help determine the side effects of the study treatment and how often they occur.

patients will receive abiraterone acetate and prednisone orally, once daily for 2 months (2 cycles) on an outpatient basis. at the start of cycle 3, dutasteride will be taken once daily. patients will return to the clinic on day 14 of the first 3 cycles for routine blood tests. patients will come to the clinic every 12 weeks for a ct scan and/or x-ray of the chest, ct scan or mri of the abdomen and pelvis, bone scan, and blood test for testosterone and other specialized blood test.

Eligibility criteria:
inclusion criteria: * diagnosis of adenocarcinoma of the prostate * castrate resistant disease * metastatic disease * normal organ and marrow function * subjects with partners of childbearing potential must be willing to use adequate methods of birth control exclusion criteria: * uncontrolled intercurrent illness * uncontrolled hypertension * active or symptomatic viral hepatitis or chronic liver disease * history of pituitary or adrenal dysfunction * clinically significant heart disease * history of a different malignancy unless disease-free for at least 5 years * known brain metastasis * history of gastrointestinal disorders * prior therapy with abiraterone acetate * hiv-positive individuals on antiretroviral therapy * requirement for steroid use greater than the equivalent of 5 mg of prednisone daily * atrial fibrillation or other cardiac arrhythmia requiring therapy * thromboembolism in the last 6 months

Keywords: prostate metastatic castrate resistant
vasculaire compression system increases flow velocity in the femoral vein

Conditions: Venous Thrombosis

Summary: the objective of this clinical study was to demonstrate the performance of the vasculaire compression system to increase femoral venous peak velocity (pfv) in healthy subjects. this study was a single-arm, open label, prospective, single-center clinical study.

venous thromboembolism, e.g. deep vein thrombosis (dvt) and pulmonary embolism, occurs in approximately one in 1,000 persons in the united states annually and results in more than 250,000 hospital admissions annually in the united states. intermittent pneumatic compression (ipc), which prevents stasis in the lower limbs, has been shown to be a safe and effective method of prophylaxis of dvt in studies comparing the incidence of dvt and pulmonary embolism with and without ipc. ipc devices decrease venous stasis by augmenting the venous blood flow in the lower extremities. studies have suggested that an important indicator of the effectiveness of an ipc device in preventing dvt is the peak femoral venous velocity augmentation during the compression phase as compared with the decompression phase of the device. ipc devices produced in the early 1980s and 1990s were cumbersome, noisy and required external power sources, making them suitable only for non-ambulatory patients. furthermore, these devices have been associated with poor compliance in trauma patients in a hospital setting, and the poor compliance was associated with a higher rate of dvt. the aim of this study is to test the hemodynamic performance of a new portable ipc device, the venous health systems' vasculaire compression system. this new device is designed to provide patient comfort and convenience of use while providing similar improvement in venous blood flow when compared with existing ipc devices.

Eligibility criteria:
inclusion criteria: * male or female subjects between 18 years old and 65 years old; * capable of and willing to lay supine for approximately one hour; * subjects must provide written informed consent exclusion criteria: * history of deep vein thrombosis (dvt) or suspected dvt; * history of vascular disease, e.g. coronary or peripheral artery disease; * history of stroke; * history of pulmonary edema; * history of congestive heart failure; * diabetes mellitus; * past or present smoker; * surgery or trauma to the right leg within the last six months; * open ulcers or wounds on the right leg; * pregnant or breastfeeding.

Keywords: deep vein thrombosis effects of compression therapy peak flow velocity
effectiveness and safety of a single-center clinical study on a cd25 monoclonal antibody-containing gvhd prophylaxis scheme to reduce the incidence of severe acute gvhd after umbilical cord blood transplantation for malignant hematologic diseases

Conditions: Acute Graft Versus Host Disease; Malignant Hematologic Neoplasm

Summary: evaluating the safety and effectiveness of a cd25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (agvhd) regimen following unrelated umbilical cord blood transplantation (ucbt) for malignant hematologic disorders in reducing severe agvhd.

acute graft-versus-host disease (agvhd) is a major complication and leading cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation (allo-hsct). preliminary research findings suggest that the addition of cd25 monoclonal antibody at +3 days post unrelated umbilical cord blood transplantation (ucbt) has reduced the incidence of grade iii-iv agvhd compared to previous protocols. in order to further explore how to improve prevention strategies of agvhd and reduce the incidence of severe agvhd, we performed this study to evaluate the safety and effectiveness of a prophylactic gvhd regimen utilizing cd25 monoclonal antibody post-ucbt for malignant hematologic disorders, aimed at reducing the incidence of severe agvhd.

Eligibility criteria:
inclusion criteria: * malignant hematologic disorders; * patients undergoing ucbt; * female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the following year. exclusion criteria: * non-malignant hematologic disorders; * history of allogeneic hematopoietic stem cell transplantation or solid organ transplantation; * uncontrolled bacterial, viral, or fungal infections. "uncontrolled" is defined as lack of clinical improvement or progression despite adequate antimicrobial therapy; * hiv infection or active hepatitis b or c virus infection; * pregnant or lactating women; * substance abusers; subjects with uncontrolled psychiatric disorders; individuals with cognitive dysfunction; * participation in similar clinical studies within the past 3 months; * subjects deemed unsuitable by the investigator (e.g., those expected to be unable to adhere to treatment due to financial constraints).
sugammadex reversal of neuromuscular blockade and postoperative bleeding

Conditions: Blood Coagulation Tests ( INR, APTT)

Summary: sugammadex is new drug that is used for reversal of rocuronium induced muscle relaxation. benefits of reversal of neuromuscular blockade appears to be of great value in living donor liver transplant recipients. however, few clinical reports have investigated the anticoagulant effect of sugammadex. in this study, effects of sugammadex on bleeding profile of living donor liver transplantation will be investigated.


Eligibility criteria:
inclusion criteria: * all candidates for living donor liver transplantation exclusion criteria: * massive intraoperative bleeding manifestations of early graft dysfunction
tms treatment in multiple system atrophy with fatigue

Conditions: Transcranial Magnetic Stimulation; Multiple System Atrophy; Fatigue

Summary: transcranial magnetic stimulation (tms) is a procedure that has been shown to improve fatigue in chronic sufferers. it uses a plastic covered coil that sends a magnetic pulse through the skull into the brain and by targeting particular areas in the brain it can be used to help modulate the perception of fatigue. the study intends to use this technique to treat such a disabling symptom in patients who suffer from multiple system atrophy (msa). initially the aim is to study this technique in 22 msa patients who are suffering from fatigue . these patients would require an resting-state funtional mri before and after the stimulation. the stimulation would be performed ten sessions and the patients would be assessed by a clinician using well recognized clinical tools. it is anticipated that there will be a meaningful improvement in fatigue. it is also anticipated that tms is a safety technique to use in msa patients . our findings will revealed that fatigue may be associated with an altered default mode network and sensorimotor network connectivity in msa patients. we hypothesize that these divergent motor and cognitive networks connectivity changes and their adaptive or maladaptive functional outcome may play a prominent role in the pathophysiology of fatigue in msa.


Eligibility criteria:
inclusion criteria: 1. patients with multiple system atrophy diagnosed as "possible" or "probable" according to the 2008 mds clinical diagnostic criteria; 2. age ≥30aged ≤ 75years old; 3. right handedness 4. mmse\>24 5. the dosage and species of anti-parkinson drug is maintained during the treatment; 6. the patient or his/her legal guardian agreed to participate in the trial and signed the informed consent.ability to follow research plans and visit plans. 7. fss≥4 exclusion criteria: 1. serious medical and mental illness; 2. history of stroke, intracranial tumor and other central nervous system; 3. patients with suicidal tendencies and psychotic symptoms. 4. mri for contraindications, such as metal implants, claustrophobia, etc 5. contraindications for tms (such as history of seizures, pregnant women, installation of pacemakers, metal inclusions in the body, intracranial hypertension, severe bleeding tendency, etc.) 6. patients who received tms treatment for nearly half a year.

Keywords: tms,msa,fmri,fatigue,functional, connectivity
study of 111in-dac as a medical imaging agent for the detection of breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to investigate the safety and imaging ability of 111in-dac when used with planar and spect imaging for the detection of breast cancer.


Eligibility criteria:
inclusion criteria patients will be eligible for the study if they: * are non-pregnant, non-lactating females 18 years of age or older(must agree to use an appropriate and effective method of birth control during the study and for 2 weeks after study) * are being evaluated for a known or suspected breast tumor (must present with either a mammographic abnormality 10mm or larger or a mammographically occult but palpable abnormality of the breast) * have been previously scheduled for biopsy or surgical excision of the known or suspected tumor of the breast * have signed an informed consent form exclusion criteria patients will not be eligible for this study if they: * have a history or suspicion of significant allergic reaction or anaphylaxis to any of the 111in-dac components * have a clinically unstable medical condition or opportunistic infection, a life-threatening disease state, impaired renal or hepatic function or are immunosuppressed * are taking or have taken part in any investigational study within 30 days of start of study * have received an indium agent within 30 days of start of study * are not able to remain immobile during scanning time * have taken drugs that may damage the kidneys within 2 weeks of start of study * have abnormal laboratory test results: hemoglobin \ 1.5 mg/100ml, alkaline phosphatase 2x the upper limit of normal * have undergone an excisional and/or needle localization biopsy within 4 days prior to start of study
polycystic ovary syndrome and betatrophin

Conditions: Polycystic Ovary; Obesity

Summary: this is an original study giving an information about the association body mass index, polycystic ovary syndrome and betatrophin.

introduction: betatrophin is a protein hormone which has a significant role in glucose homeostasis and lipid metabolism. the aim of this study is to compare the levels of serum betatrophin in overweight and normal weight women with pcos. material and method: thirty-five patients normal weight women with pcos (bmi\<25) and 38 obese women with pcos (bmi≥25) were included in this prospective, cross-sectional study. patients were selected according to rotterdam criteria. serum betatrophin levels were studied by elisa method and then compared between these two groups besides the following additional parameters as waist circumference/hip circumference ratio, fasting blood glucose, 75 g ogtt (oral glucose tolerance test) results and homa-ir levels.

Eligibility criteria:
inclusion criteria: -polycystic ovary syndrome according to 2003 rotterdam pcos consensus diagnostic criteria exclusion criteria * pregnancy, * an additional systemic disease (i.e.,hyperprolactinemia, thyroid dysfunction, liver or kidney diseases, cardiovascular disease, hyperlipidemia, type 1 or type 2 diabetes, chronic or acute infection within the previous 30 days), * morbid obesity, * smoking, * the use of medications for contraception, androgen excess, hypertension, hyperglycemia or dyslipidemia at least 3 months before the study.

Keywords: betatrophin pcos obesity insulin resistance